PREDICT S.p.A.

Investor Presentation

June 2026

KT&Partners Annual Investors Summit Day

AT A GLANCE

Hi-Tech solutions for advanced diagnostics

Predict S.p.A., based in Bari, is an innovative SME active in the med-tech sector, specializing in non-invasive in vivo diagnostics. It markets medical imaging systems for screening, providing technical assistance, and develops innovative technologies in the fields of ***breath analysis*** and ***digital healthcare***.

€0.84mn invested in R&D in 2025

~20years of partnership with GE HealthCare

3 patents

28 Highly qualified employees*

*As of 31/12/2025

4 Strategic Business Units

Traditional

Imaging

Distribution of **diagnostic equipment** (for ultrasound, X-rays, and magnetic resonance imaging).Training of healthcare personnel.

People Support

Technical assistance and after-sales services, maintenance, repair, and add-ons. **Predictive healthcare** and hospital **disinfection solutions**.

Innovative

Mistral

Development and sale of advanced **breath analysis** solutions for the early screening of diseases.

Digital Healthcare

Development and sale of **innovative** solutions in augmented reality, holography, and collaborative **robotics** to improve healthcare services.

PREDICT LIFE CARE

MILESTONES

2008
PREDICT WAS FOUNDED

2008
SUBSCRIPTION OF AGENCY MANDATE FOR GE

2012
AFTER-SALES SERVICES FOR GE MACHINERY

2016 - 2018
MISTRAL, OPTIP & APHEL DEVELOPING

2020
FIRST ROBOT INSTALLATION

2021
DELIVERY OF FIRST SAMPLER

2023
OPTIP STAGE AND MISTRAL LAB

2024
INNOVATIVE SME AND IPO ON EGM

2025
NEW MILAN OFFICE | TEAM EXPANSION | BUYBACK LAUNCH

DISTRIBUTION AGREEMENTS
Shenzhen Spinq | Airs Medical EU | UVC Solutions | Caresmed
ORDERS/CONTRACTS
2 Mistral Samplers+services (IRCCS Bari) | MQ Analyzer (DIF Bari) | 2 Mistral Samplers PoliBA | 3 Robots Corporea Museum (NA) | LiberAUT Project | RTI Tender «AMiCa» | Fetal ultrasound «IAUSO» | Exprivia RTI Tender ICT services «InnovaPuglia»
CALLS
PNRR S4D Precision Diagnostic | PNC D3-4Health
TRIALS
EMICENTER Project | ASMA Trial (Foggia) | Head-neck cancer study (IFO Roma)

2026

AGREEMENTS
- Network contract with Weatecho for Hospital 4.0

AWARDS
- Supply of ultrasound teleradiology services for Niguarda, OPTIP Bodycam platform for ASL Foggia,11 ultrasound scanners for ASL BAT.

TRIALS
- 1st study of Mistral for occupational medicine in the automotive sector at COM in Milan

START-UP | **RESEARCH AND DEVELOPMENT** | **CONSOLIDATION AND INNOVATION**

PREDICT LIFE CARE

INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL

Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes.

SUPPLIERS → UNIVERSITIES IRCCS HOSPITALS → PREDICT LIFE CARE → CUSTOMERS → PATIENTS AND CITIZENS

4
Strategic Business Units

Imaging	**Mistral**
People Support	**Digital Healthcare**
2 SBU with established solutions to provide **stable & recurring revenues**	**2 SBU** with innovative solutions in **growing markets**

DISRUPTIVE INNOVATION HI-TECH IN THE HEALTHCARE WORLD

The Predict model enables a balanced and efficient management of resources and innovation:

- Each **SBU** has a structured management control system.
- Investments in innovation are planned considering the SBUs and their impact on the business.

STRATEGIC BUSINESS UNITS

The activities of Predict are divided into 4 Strategic Business Units:

SBU	Traditional		Innovative	
	Imaging	**People Support**	**Mistral**	**Digital Healthcare**
Activity description	• **Sale** of **medical imaging equipment*,** marketed in the field of **in vivo diagnostic imaging.** • **Distribution agreements** with GE HealthCare, Fora S.p.A. and Caresmed S.r.l. • **Solutions:** ultrasound systems, X-ray, CT, MRI, PET, mobile units rental services, densitometers and bioimpedance meters • **Med-tech education** and training * new/used, for private custumers only	• **Technical support** for the installed **imaging** equipment (installations, calibrations, electrical safety checks) and **repair** (for innovative SBUs) • **Sales** of **spare parts** and **add-ons** • **Predictive Healthcare Solutions MRI** (**AI**) • **Solutions** for the **disinfection** of **hospital environments**	• **Development, design & commercialization** of screening solutions based on proprietary technology for **breath analysis: Mistral Sampler** for VOC sampling, **Mistral Analytics** for medical history. • **Owned Mistral Lab** and the construction of **"turnkey"** breath analysis laboratories for **polyclinics, IRCCS, CRC** • **Clinical trials and prototypes** • **Research partnerships** with universities to evolve and integrate technologies	• **Development and sale** of solutions based on remote communication through augmented reality **(Optip)** and robotics **(Aphel**), also on active ageing (home robotics services) • **Optip**: Interaction in holographic presence (AR, VR, MR technologies). Holographic stages for training and education. • **Aphel**: AI platform that integrates humanoid and collaborative robots • **Commercialization** of **Quantum computers** in the education & healthcare sector
KPIs	**Revenue** **FY25** **71% → € 5.4 mn**	**Revenue** **FY25** **15% → € 1.2 mn**	**Revenue** **FY25** **3% → € 0.2 mn**	**Revenue** **FY25** **11% → € 0.8 mn**

Sample collectors:

PREDICT LIFE CARE

PRODUCTS AND APPLICATION PORTFOLIO

Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment.

	Traditional		Innovative	
SBU	**Imaging**	**People Support**	**Mistral**	**Digital Healthcare**
Products	GE HealthCare, CARESMED		Mistral Sampler; Mistral LAB; Mistral Analytics	OPTIP: Optip Surgery, Optip Streambox, Optip Probe, Optip Stage; APHEL: Aphel (Helios, Hermes, Mini); SPINQ: Quantum computers distribution
Application areas	ultrasounds: gynecology, cardiology, general imaging, point of care	X-rays: mammography	oncological diseases; metabolic disorders; early diagnosis	tele-ultrasound; telemedicine; patient-care; child neuropsychiatry; active ageing; innovative education; non-pharmacological support; pediatric oncology & hematology

Mistral Sampler

Mistral LAB

Mistral Analytics

Optip Surgery

Optip Streambox

Optip Probe

Optip Stage

Aphel

Helios Hermes Mini

Quantum computers distribution

PREDICT LIFE CARE

SYNERGIES BETWEEN THE DIFFERENT SBUs

Supply of integrated Tele-ultrasound solutions with OPTIP products connected via Streambox to GE HealthCare ultrasound machines

After-sales assistance provided by the People Support SBU for products offered by the Imaging SBU (assistance, repair, and spare parts sales)

Integrated offerings for the screening of certain cancers using both traditional imaging techniques and breath analysis techniques.



After-sales assistance provided by the People Support SBU for products offered by the Digital Healthcare SBU
(assistance and repair)

After-sales assistance provided by the People Support SBU for products offered by the Mistral SBU (assistance and repair)

PREDICT LIFE CARE

External benefits: 1. Increased efficiency of healthcare processes. 2. Support for public healthcare with new paradigms (+demand vs -resources)

VALUE CHAIN AND BUSINESS PROCESS

Predict sells its products both through direct orders from private customers and through bids open to public and private entities.

PREDICT LIFE CARE

SUPPLIERS AND CLIENTS

SUPPLIERS

- ✓ Manufacturers of Imaging Equipment
- ✓ Companies providing in vivo diagnostic Imaging services
- ✓ Manufacturers of systems for gas chromatography and mass spectrometry analysis
- ✓ Players in the hospital disinfection sector through ultraviolet radiation
- ✓ Manufacturers of humanoid robots and collaborative robots
- ✓ Manufacturers of augmented reality headsets
- ✓ Software & Hardware companies

R&D VALIDATION

CLIENTS

PUBLIC:

- ✓ university clinics
- ✓ IRCCS
- ✓ Public Hospitals
- ✓ Universities
- ✓ Primary and Secondary Schools

PRIVATE:

- ✓ Hospitals
- ✓ Clinics
- ✓ Specialized outpatient centers
- ✓ Specialized medical practices
- ✓ Insurance companies
- ✓ Healthcare professionals
- ✓ Analysis Laboratories
- ✓ Hi-tech healthcare companies

RESEARCH AND DEVELOPMENT

R&D

Partnership with hospitals, IRCCS, universities

Investments 2019-25

€ 4.81mn~

MISTRAL

- **2016-21:** completed breath sample collection system (Mistral Sampler) and CE mark
- **4Q21 -1H22:** Mistral Lab breath analysis laboratory built and launched
- **3Q22:** Process automation of the Lab's examination procedures
- **1Q23:** AI algorithms have been defined to perform automatic analysis (Mistral AI) on breath samples
- **FY23:** Multicentric clinical trials have been initiated for validation on prostate cancer
- **FY24:** Qualitative and semi-quantitative identification of a set of molecules representative of the pathologies investigated; start of clinical trials for other studies
- **FY25:** Clinical trials on asthma, pilot study on head and neck cancers, development of AI-based and machine learning algorithms for major cancers (colorectal, lung, prostate, breast), integration of advanced QEPAS sensors, management software testing



DIGITAL HEALTHCARE

- **2017-19:** Optip solution developed based on the Hololens AR headset. AI platform implemented for Ubtech robot, now known as 'Aphel Helios'
- **FY20:** Temi robot integrated into the Aphel platform, now known as 'Aphel Hermes'
- **2020-23:** The first ABB collaborative robot has been integrated into the Aphel family, now known as 'Aphel Kronos'
- **FY23:** Developed the 'Optip Stage' solution (holograms without a headset). AI-based project to guide ultrasound technicians
- **FY24:** Launched project for a robotic system for remote ultrasound; integration of collaborative robotics, computer vision, and deep learning.
- **FY25:** Feedback from ultrasound system installations, AI-assisted box platforms, launch of bodycams in Emergency Departments and ambulance services, introduction of Aphel Alpha Mini, start of the CURES research project

Co-financing for innovation

PIA - Smart Diagnostic System
Contribution: €2.02mn
Period: 10/2021-12/2024

D3-4HEALTH (Endoscope Project)
Contribution: €266k
Period: 10/2024-10/2025

HEAL ITALIA
Contribution: €212k
Period: 08/2024-11/2025

PREDICT LIFE CARE

PATENTS AND CE TRADEMARKS

OPTIP

08/2017
Filing of European patent application

08/2018
Filing of international PCT patent application

12/2019
Filing of CE trademark

02/2020
Filing of CE trademark for the new product release

09/2021
Patent granted in the USA, no. 11,122,164 B2

03/2023
Utility model granted in Italy no. 202023000000231

Mistral
INSIDE THE BREATH

12/2018
Filing of International PCT patent application, converted into European patent application no. EP3873347

02/2019
Filing of CE trademark

02/2022
Patent granted and validated in: Spain; Switzerland; Austria; United Kingdom; Germany; Netherlands; France; Italy

10/2025
Filing of a **patent** application for a sampler with real-time VOCs analysis

2026
Breath analysis technologies patents in progress

REFERENCE MARKETS AND DRIVERS

Predict operates in 3 market niches in the Healthcare sector, growing globally:

1 Imaging

2 Breath analysis

3 Digital Health Tech

At International level



Source: Fortune Business Insights, 2022 - World Bank, 2021



Source: LIUC, 2023



Source: Grand View Research, 2021

In Italy

The ultrasound market in Italy in 2023 was estimated by **COCIR** at **€180 mln**. GE HealthCare has an estimated market share of around 24%, with Predict being the exclusive distributor in Puglia. 42% market share of the market in Puglia estimated for Predict.

Trend**: increase in the demand** for Breath Analysis services as a tool for screening oncological diseases, thanks to the use of **non-invasive** breath biopsy technologies.

Over **€12 billion from the PNRR** allocated to **personnel training** with technologies for **efficiency improvements**, aimed at addressing the staff shortage in the **SSN**

Driver

- ✓ Increase in life expectancy
- ✓ Obsolescence of equipment, productivity improvement
- ✓ Growth of private and accredited facilities offering diagnostic services
- ✓ Expansion of equipment usage opportunities (territories and diagnostic fields)

- ✓ Statistical increase in affected diseases
- ✓ Higher demand for non-invasive techniques
- ✓ High degree of accuracy compared to traditional screening (biomarkers)
- ✓ Versatility of the methodology that enables the optimization of healthcare spending and expansion into unexplored areas

- ✓ Need for digital alternative medicine solutions
- ✓ Decrease in the number of healthcare workers
- ✓ Opportunities for new services provided through the combination of medicine and technology
- ✓ New teaching methods to accelerate medical training

PREDICT LIFE CARE

MANAGEMENT TEAM & KEY PEOPLE

Angelo Gigante
Founder, President, CEO

20+ years of experience

2008: founds Predict
2003-2007: sales in GE HealthCare
2000-2003: R&D as Consultant Engineer, software designer
Master's Degree in Electronic Engineering at PoliBa

Isabella Cafagna
Vice President and CEO
Director SBU Mistral, SBU Digital Healthcare

10+ years of experience

2015-today: Sales Account Manager, Sales Manager, SBU Mistral Director for Predict
Master's Degree in Chemistry atUniBA
PhD in Environmental Engineering and Chemistry PoliBa

Loredana Amoruso
CEO
Tender and Legal Affairs Manager

10+ years of experience

2015-today: public tender specialist, legal affair, Legal Department Manager, Tenders Office, Trademarks and Patents for Predict
2009: Registered with the Bar Association of Bari
Master's degree in Law UniBA

Angelo Ceci
Chief Financial Officer and
Investor Relations Manager

2 years of experience

2023: Joins Predict in Finance & Control
Degree in Economics and Management, University of Trento

Giuseppe Carella
Director, Special Attorney
Director SBU Imaging

10+ years of experience

2014-today: Technical Assistance, Sales for Services, SBU People Support Service Manager, SBU Imaging Sales Manager
2024: Board Member of Predict
Master's degree in Chemistry, UniBA

Daniele Volpicella
Service Manager
SBU People Support

9 years of experience

2016: SBU Imaging Sales Manager 2024: SBU People Support Service Manager Diploma in Industrial Technical Expert with specialization in Electrical Engineering and Automation

SHAREHOLDING AND GOVERNANCE

SHAREHOLDING

Angelo Aurelio Gigante — 51%
Paola Sciancalepore — 49%

Qo3 S.r.l. — 76.94% *
Treasury shares — 0.62% *
Market — 22.43% *

PREDICT LIFE CARE

Data updated as of 28th May 2026

***% on the total shares.**
- Qo3 S.r.l.: 76.94% of total shares | 69.58% ordinary shares | 84.30% voting rights
- Treasury shares: 0.62% of total shares | 0.82% ordinary shares | 0.43% voting rights
- Market (float): 22.43% of total shares | 29.60% ordinary shares | 15.27% voting rights

GOVERNANCE

Board of Directors**

Angelo Aurelio Gigante
President and CEO

Isabella Cafagna
Vice President , Executive Director

Loredana Amoruso
Executive Director

Rocco Dichio
Director

Valeria Stucci
Director

Giuseppe Carella
Director, Special Attorney

Vito Anelli
Independent Director

Board of Statutory Auditors**

- President: F. Sanseverino
- Statutory Auditor: R. Pierno
- Statutory Auditor: M. T. Rizzi
- Alternate Statutory Auditor: M. Secchi
- Alternate Statutory Auditor: V. Virzi

Supervisory Committee

- President: Atty. F. Di Marzio
- Atty. E. De Tommaso
- Atty. S. Pellegrino

Audit Firm***

BDO

Sustainability Report

Approved by the BoDs on April 23, 2026

**In office until the approval of the financial statements as of 31/12/2026
***In office until the approval of the financial statements as of 31/12/2027

ESG

E

Scope 1 Emissions
65 tCO_2e tot. | 2.4 tCO_2e per FTE

Scope 2 Emissions
14.1 tCO_2e tot. | 0.52 tCO_2e per FTE

Energy Efficiency
Building energy class improved from F to A1

Procurement
Adoption of the **Sustainable Procurement Manual**

Waste
Ongoing agreement with a **local company for** special **waste treatment**

S

Production Bonuses
Implementation of a **PDR** linked to the **achievement** of **EBITDA-related objectives**

Corporate Welfare
Internal events (Predict Kick-off, Sunset Party, Summer Race) and flexible work policies

Childcare Project
Donation of innovative equipment to **associations and schools**

Employee Training
Mandatory **training courses** conducted by the Palo Alto

G

Gender Equality Committee
40% Male Employees
60% Female Employees

ESG Committee
Key people involved in defining **ESG goals** and drafting the **Sustainability Report**

Code of Ethics and Legislative Decree 231
Updated to reflect new transparency and accountability requirements

Stakeholder Engagement
Adoption of **engagement policies** on sustainability topics

Certifications

ISO 9001:2015
ISO 13485:2016
ISO 14001:2015
ISO/DIS 30415
PDR 125:2022
ISO 27001

Planned ESG Objectives for 2026: fleet 20% hybrid vehicles, Mistral materials re-engineering, product penetration testing, employee cybersecurity training

GROWTH STRATEGIES

Internal growth

Development of innovative SBUs with a focus on Mistral

- R&D and partnerships with clinical research centers
- Hiring of new professional roles, strengthening of commercial functions, and product development
- Implementation of a network of Mistral Labs in Italy
- Development of partnership agreements with pharmaceutical companies

Expansion of the hi-tech solutions offering

- Consolidation of the leadership position in the offering of hi-tech solutions through the expansion of the product range and the provision of training courses

Strengthening of traditional SBUs and cross-selling

- Diversification of product types, differentiating suppliers, and expanding the geographic markets served.
- Development of internal synergies to increase cross-selling activities between products and services to enhance customer loyalty and improve profitability.

External growth

M&A

- Evaluation of potential acquisitions in breath analysis and digital healthcare to gain complementary know-how and expand market share

FINANCIAL HIGHLIGHTS FY25 vs FY24 & FY23

Revenue / VoP (€mn)



EBITDA (€mn)



Net Result (€mn)



NFI / NFI Adj. (€mn)



Equity (€mn)

FY2025 vs FY2024 INCOME STATEMENT

Reclassified Income Statement (Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. % FY25-FY24
Sales Revenues	**7,595**	**100.0%**	**6,626**	***100.0%***	**14.6%**
Increases in fixed assets for internal work	581	7.7%	-	*0.0%*	n/a
Other revenues and income	697	9.2%	712	*10.7%*	-2.1%
Value of Production	**8,874**	**116.8%**	**7,337**	***110.7%***	**20.9%**
Costs of raw materials, components, consumption and merchandise	(4,736)	-62.4%	(4,245)	*-64.1%*	11.6%
Cost of services	(1,545)	-20.3%	(1,263)	*-19.1%*	22.3%
Use of third-party assets	(136)	-1.8%	(112)	*-1.7%*	21.4%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	101	1.3%	271	*4.1%*	-62.7%
Personnel Expenses	(1,755)	-23.1%	(1,149)	*-17.3%*	52.7%
Other operating expenses	(25)	-0.3%	(31)	*-0.5%*	-19.4%
EBITDA **	**779**	**10.3%**	**808**	***12.2%***	**-3.6%**
Depreciations and write-downs	(563)	-7.4%	(294)	*-4.4%*	91.5%
EBIT ***	**216**	**2.8%**	**514**	***7.8%***	**-58.0%**
Financial income	14	0.2%	(39)	*-0.6%*	>100.0%
EBT	**230**	**3.0%**	**475**	***7.2%***	**-51.6%**
Income taxes	(60)	-0.8%	(139)	*-2.1%*	-56.8%
Net Result	**171**	**2.2%**	**336**	***5.1%***	**-49.1%**

(*) Percentage incidences calculated on sales revenues and service revenues. (**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them. (***) EBIT represents the result before income taxes and financial income and charges. EBIT therefore represents the result of operating activities before the remuneration of both third-party and own capital. EBIT is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBIT is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.(****) EBT represents the result before income taxes and deferred taxation.

FY2025 vs FY2024 SBU INCOME STATEMENT

Imaging

SBU Imaging Income Statement (Data in Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. % FY25-FY24
Sales Revenues	5,369	*100.0%*	5,173	*100.0%*	3,8%
Increases in fixed assets for internal work	–	*0.0%*	-	*0.0%*	n/a
Other revenues and income	78	*1.4%*	23	*0.4%*	>100,0%
Value of Production	**5,447**	***101.4%***	**5,197**	***100.4%***	**4,8%**
Costs of raw materials, components, consumption and merchandise	(3,567)	*-66.4%*	(3,660)	*-70.7%*	-2.5%
Cost of services	(503)	*-9.4%*	(431)	*-8.3%*	16.7%
Use of third-party assets	(40)	*-0.7%*	(26)	*-0.5%*	53.8%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	41	*0.8%*	244	*4.7%*	-83.2%
Personnel Expenses	(398)	*-7.4%*	(254)	*-4.9%*	56.7%
Other operating expenses	(7)	*-0.1%*	(19)	*-0.4%*	-63.2%
EBITDA**	**973**	***18.1%***	**1.051**	***20.3%***	**-7.4%**

(*) Percentage incidences calculated on sales revenues and service revenues.
(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

PREDICT LIFE CARE

FY2025 vs FY2024 SBU INCOME STATEMENT

People Support

SBU People Support Income Statement (Data in Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. % FY25-FY24
Sales Revenues	1,151	*100.0%*	905	*100.0%*	27.2%
Increases in fixed assets for internal work	–	*0.0%*	-	*0.0%*	n/a
Other revenues and income	17	*1.5%*	5	*0,5%*	>100.0%
Value of Production	**1.168**	***101.5%***	**910**	***100.5%***	**28.4%**
Costs of raw materials, components, consumption and merchandise	(554)	*-48.1%*	(361)	*-39.9%*	53.5%
Cost of services	(172)	*-14.9%*	(110)	*-12.1%*	56.4%
Use of third-party assets	(21)	*-1.9%*	(17)	*-1.9%*	23.5%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	33	*2.9%*	19	*2.1%*	73.7%
Personnel Expenses	(272)	*-23.7%*	(182)	*-20.1%*	49.5%
Other operating expenses	(4)	*-0.3%*	(5)	*-0.5%*	-20.0%
EBITDA **	**178**	***15.5%***	**254**	***28.1%***	**-29.9%**

(*) Percentage incidences calculated on sales revenues and service revenues.
(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

PREDICT LIFE CARE

FY2025 vs FY2024 SBU INCOME STATEMENT

Mistral

SBU Mistral Income Statement (Data in Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. % FY25-FY24
Sales Revenues	242	*100.0%*	258	*100.0%*	-6.2%
Increases in fixed assets for internal work	360	*148.8%*	-	*0.0%*	n/a
Other revenues and income	269	*111.0%*	421	*163.5%*	-36.1%
Value of Production	**870**	***359.7%***	**679**	***263.5%***	**28.1%**
Costs of raw materials, components, consumption and merchandise	(96)	*-39.8%*	(76)	*-29.6%*	26.3%
Cost of services	(441)	*-182.3%*	(341)	*-132.2%*	29.3%
Use of third-party assets	(37)	*-15.1%*	(32)	*-12.4%*	15.6%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	(0)	*-0.1%*	(0)	*0.0%*	n/a
Personnel Expenses	(639)	*-263.9%*	(399)	*-154.8%*	60.2%
Other operating expenses	(8)	*-3.2%*	(5)	*-1.8%*	60.0%
EBITDA **	**(350)**	***-144.7%***	**(173)**	***-67.3%***	**>100.0%**

(*) Percentage incidences calculated on sales revenues and service revenues.
(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

PREDICT LIFE CARE

FY2025 vs FY2024 SBU INCOME STATEMENT

Digital Healthcare

SBU Digital Healthcare Income Statement (Data in Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. % FY25-FY24
Sales Revenues	833	*100.0%*	290	*100.0%*	>100.0%
Increases in fixed assets for internal work	221	*26.6%*	-	*0.0%*	n/a
Other revenues and income	334	*40.1%*	263	*90.8%*	27.0%
Value of Production	**1,388**	***166.7%***	**552**	***190.8%***	**>100.0%**
Costs of raw materials, components, consumption and merchandise	(520)	*-62.4%*	(147)	*-50.9%*	>100.0%
Cost of services	(428)	*-51.4%*	(380)	*-131.1%*	12.6%
Use of third-party assets	(38)	*-4.5%*	(37)	*-12.9%*	2.7%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	28	*3.3%*	8	*2.8%*	>100.0%
Personnel Expenses	(446)	*-53.6%*	(314)	*-108.3%*	42.0%
Other operating expenses	(6)	*-0.8%*	(4)	*-1.3%*	50.0%
EBITDA **	**(22)**	***-2.7%***	**(321)**	***-110.9%***	**-93.1%**

(*) Percentage incidences calculated on sales revenues and service revenues.
(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

PREDICT LIFE CARE

FY2025 vs FY2024 BALANCE SHEET

Riclassified Balance Sheet (Euro/000)	31.12.2025	%(*)	31.12.2024	%(*)	Var. %FY25-FY24
Intangible fixed assets	1,052	41.5%	790	39.4%	33.2%
Tangible fixed assets	534	21.1%	563	28.1%	-5.2%
Financial fixed assets	702	27.7%	633	31.6%	10.9%
Net fixed assets **	**2,289**	**90.3%**	**1,987**	**99.1%**	**15.2%**
Inventory	943	37.2%	843	42.0%	11.9%
Trade receivables	2,154	85.0%	2,022	100.9%	6.5%
Trade payables	(2,487)	-98.1%	(3,546)	-176.9%	-29.9%
Trade working capital	**611**	**24.1%**	**(682)**	**-34.0%**	**>100.0%**
Other current assets	1,314	51.8%	1,472	73.5%	-10.7%
Other current liabilities	(1,606)	-63.3%	(715)	-35.7%	>100.0%
Net Tax receivables and payables	453	17.9%	235	11.7%	92.8%
Accruals and deferred income	(295)	-11.6%	(47)	-2.4%	>100.0%
Net working capital ***	**478**	**18.8%**	**263**	**13.1%**	**81.7%**
Termination indemnity/severance pay	(209)	-8.3%	(223)	-11.1%	-6.3%
Provisions for risks and charges	(22)	-0.9%	(22)	-1.1%	-
Net Invested Capital ****	**2,535**	**100.0%**	**2,004**	**100.0%**	**26.5%**
Loans from banks	–	–	371	18.5%	-100.0%
Other current financial assets	–	–	–	-	n/a
Cash and cash equivalents	(1,840)	-72.6%	(2,576)	-128.5%	-28.6%
Net financial Indebtedness *****	**(1,840)**	**-72.6%**	**(2,205)**	**-110.0%**	**-16.6%**
Integrated Incentive Program (PIA) contribution	(202)	-8.0%	(1,009)	-50.3%	-80.0%
Financial receivables from Evholo	–	–	(38)	-1.9%	-100.0%
Net financial Indebtedness Adjusted	**(2,041)**	**-80.5%**	**(3,251)**	**-162.2%**	**-37.2%**
Share capital	135	5.3%	130	6.5%	3.8%
Reserves and retained earnings	2,580	101.8%	2,254	112.4%	14.5%
Share Premium Reserve	1,489	58.7%	1,489	74.3%	-
Net profit	171	6.7%	336	16.8%	-49.1%
Equity	**4,375**	**172.6%**	**4,209**	**210.0%**	**3.9%**
Total sources	**2,535**	**100.0%**	**2,004**	**100.0%**	**26.5%**

(*) Percentage incidences calculated on Net Working Capital, deferred/anticipated items and other non-current assets. (**) Net Fixed Assets is calculated as intangible, tangible and financial fixed assets. (***) Net Working Capital is calculated as the sum of inventories, trade receivables, trade payables, other current assets, other current liabilities, tax receivables and payables, and accrued income and prepaid expenses. Net Working Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter. (****) Net Invested Capital is calculated as Net Working Capital, Net Fixed Assets and Non-current Liabilities (which also include deferred and anticipated taxation). Net Invested Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter.

(*****) Net Financial Indebtedness is calculated as the sum of (i) cash and cash equivalents, (ii) financial liabilities, and has been determined in accordance with the provisions of the "Guidelines on disclosure obligations under the Prospectus Regulation" (ESMA32-382-1138) published by ESMA (European Securities and Markets Authority or European Supervisory Authority of financial instruments and markets).

INVESTMENT HIGHLIGHTS

High-growth markets in Healthcare
Strong demand for diagnostic technologies, leading to efficient offerings at lower costs

"Turnkey" solutions
for breath analysis laboratories at University Hospitals, IRCCS, and Clinical Research Centers

High level of know-how and track record
acquired by top management, strengthened by the partnership with GE HealthCare

Pioneer and first-mover into new markets
Offering unique and innovative solutions through technological expertise and synergies between the different SBUs

Distinctive positioning and versatility
Predict is the only company offering breath analysis solutions for hundreds of different molecules, standing out in medical technologies across Europe

Unique value proposition for innovation
Wide range of detectable diseases and clinical fields of application

KEY TAKEAWAYS

2025

Main Achievements:

SBU Imaging:
- Agreement with Caresmed for the distribution of new technologies for the prevention of chronic diseases (Puglia, Basilicata)

SBU People Support:
- Expansion in the distribution of sterilization devices and AI-powered MRI enhancement software

SBU Mistral:
- Awarded the D3-4Health call with the Endoscope project
- Delivery of the MQ Analyzer prototype to the University of Bari
- Supply of 2 Mistral Samplers & services to IRCCS Bari, 2 Mistral Samplers to PoliBA

SBU Digital Healthcare:
- First remote echocardiography in Italy with Optip (ASL Lecce)
- Stronger positioning of digital products for schools (Didacta Fair 2025)
- Neonatal screening results from “Giovanni XXIII” Hospital (Bari)
- RTI win for home care and active ageing (Policlinico Bari)
- Awarded LiberAUT project (autism rehabilitation)
- Distribution deal with Spinq (quantum computers)
- RTI framework agreement with Exprivia for ICT services (InnovaPuglia)
- Delivery of 3 Robots to Corporea Museum of Naples

2026

In the next months Predict will focus on:

SBU Imaging:
- Acquisition of new clients
- Strengthening of the collaboration with GE HealthCare

SBU People Support:
- Strengthening of the workforce
- Establishment of new products/services

SBU Mistral:
- Obtaining a new patent
- Expected completion of lung and prostate cancer trials for machine learning algorithm validation
- Development of potential partnerships in the pharma and occupational medicine fields
- Launch of a network of respiratory analysis centres across Italy
- New scientific publications

SBU Digital Healthcare:
- Expansion of Aphel in educational and healthcare segments
- Application of Optip in emergency departments & ambulance services and Home Care settings
- Marketing push for product portfolio
- Development of AI-assisted ultrasound
- Second R&D project

PREDICT ON EGM

Market data

IDENTIFIERS & STOCK	
Stock code	PRE
ISIN Ordinary Shares	IT0005611071
N. Ordinary Shares	5,821,000
N. Multiple voting shares[1]	1,800,000
N. PAS[2]	60,000
IPO DATA	
Start date of trading	30/09/2024
Capital raised in IPO (pre greenshoe)	€ 1,519,500
Admission price	€ 1.00
IPO capitalization (ordinary shares)	€ 5,419,500
Euronext Growth Advisor / Specialist	Integrae SIM
DATA AS OF 12/06/2026	
Price	€ 1.15
Capitalization (ordinary shares)	€ 6,694,150

Analyst Coverage

Integrae SIM
08/04/2026

TP: €1,40 (prev. €1,45)
Upside: +84.2%
Rating: BUY

1 Special category shares issued by the Company, not listed on Euronext Growth Milan, which grant the same rights and obligations as Ordinary Shares, except that each carries three voting rights and is converted into Ordinary Shares pursuant to the rules set forth in the corporate bylaws.
2 Special category shares issued by the Company, not listed on the Euronext Growth Milan market, which confer the same rights and obligations as Ordinary Shares, except that they are non-transferable and are automatically converted into Ordinary Shares under the terms and conditions set forth in the Company's bylaws.

Source: Borsa Italiana and Factset, data updated as of 12/06/2026

PREDICT LIFE CARE

ANNEX

VIDEOS

SUPPLY OF TECHNOLOGIES FOR BREATH ANALYSIS

CONSTRUCTION OF "TURNKEY" BREATH ANALYSIS LABORATORIES

SUPPLY OF AR TECHNOLOGIES FOR TELE-ULTRASOUND

SUPPLY OF AR TECHNOLOGIES FOR EDUCATION AND TRAINING

SUPPLY OF HUMANOID ROBOTS FOR THE DEPARTMENT

PREDICT SITE

MISTRAL LAB

MARKETING MIX

		Imaging	People Support	Mistral	Digital Healthcare
Promotion	- Personal selling	✓	✓	✗	✓
	- Industry trade fairs	✓	✓	✓	✓
	- Websites	✓	✓	✓	✓
	- Dissemination	✗	✗	✓	✗
Placement	- Direct sale	✓	✓	✓	✓
	- Public Tenders	✓	✓	✓	✗
	- Specialized sellers	✗	✗	✗	✓
Pricing	- Distribution policies|Price lists	✓	✗	✗	✗
	- Tailor made / Customized	✗	✓	✓	✗
	- Fixed+renewal / Value-based	✗	✗	✗	✓

PREDICT LIFE CARE

DISCLAIMER

This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") and the information contained therein ("Information"), unless with the prior written consent of the Company, may not be used by the recipient for any purpose, nor may they be disclosed, copied, recorded, transmitted, further distributed to any other person, or published, in whole or in part, by any means or in any form and for any purpose. This presentation may contain financial information and/or operational data and/or market information regarding the business and activities of the Company and its subsidiaries. THIS PRESENTATION AND ANY RELATED ORAL DISCUSSIONS DO NOT CONSTITUTE A PUBLIC OFFERING OR AN INVITATION TO SUBSCRIBE TO, PURCHASE, OR OTHERWISE ACQUIRE FINANCIAL PRODUCTS AS REFERRED TO IN ARTICLE 1, PARAGRAPH 1, LETTER (T) OF LEGISLATIVE DECREE NO. 58 OF 24 FEBRUARY 1998, AS AMENDED. Therefore, this document is not an advertisement and does not in any way constitute a proposal to execute a contract, an offer, or an invitation to purchase, subscribe to, or sell securities, and neither it nor any part of it constitutes the basis on which to rely in relation to any contract or commitment or investment decision. The Company has not prepared and will not prepare any prospectus for the purpose of the initial public offering of securities. Any decision to purchase, subscribe to, or sell securities shall be made independently of this Presentation. Therefore, no provision of this Presentation shall create any binding obligation or liability for the Company and its affiliates and their advisors or representatives. Likewise, the presentation is not intended for distribution in the United States of America, Canada, Australia, Japan, or any jurisdiction where such distribution is unlawful (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act")). Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, or distributed, directly or indirectly, in the United States of America, its territories or possessions, or to any U.S. person. Failure to comply with this restriction may constitute a violation of U.S. securities laws. No statement or warranty, express or implied, is or will be given by the Company as to the accuracy, completeness, or correctness of the information provided, and, to the extent permitted by law and except in the case of fraud by the interested party, no liability is accepted for the accuracy or sufficiency thereof, or for errors, omissions, or inaccuracies, negligence, or otherwise, in relation thereto. In particular, but without limitation, no statement or warranty, express or implied, is or will be given as to the achievement or reasonableness of, and no reliance may be placed for any purpose on, the accuracy or completeness of estimates, objectives, projections, or forecasts and nothing in these materials should be considered as a promise or representation for the future. The information and opinions contained in this document are provided as of the date of this document and are subject to change without notice. The recipient will be solely responsible for its own assessment of the information contained in the Presentation. Neither the Company and its affiliates, nor their advisors or representatives shall be obliged to provide or update any information or to notify or correct any inaccuracies in any information. Neither the Company and its affiliates, nor any of their advisors or representatives shall have any liability to the recipient or any of its representatives as a result ofthe use or reliance on the information contained in this document. Some information may contain forward-looking statements that involve risks and uncertainties and are subject to change. In some cases, these forward-looking statements may be identified by the use of words such as "believe," "anticipate," "estimate," "target," "potential," "expect," "predict," "forecast," "project," "may," "should," "could," "shall," "will," "plan," "intend," "seek," and similar expressions. The forecasts and forward-looking statements included in this document are necessarily based on a number ofassumptions and estimates that are inherently subject to significant economic, operational, economic, and competitive uncertainties and unforeseen events, as well as assumptions relating to future business decisions subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, as they relate to events and depend on circumstances that may or may not occur in the future. Additionally, actual results may substantially differ from those contained in any forward-looking statement due to a number of significant risks and future events that are beyond the control of the Company and cannot be estimated in advance, such as the future economic environment and the actions of competitors and other parties involved in the market. These forward-looking statements speak only as of the date of this presentation. The Company cautions that forward-looking statements are not guarantees of future performance and that its current financial position, business strategy, plans, and management's objectives for future operations may differ materially from those contained or suggested by the forward-looking statements contained in this Presentation. Furthermore, even if the Company's financial position, business strategy, plans, and management's objectives for future operations are consistent with the forward-looking statements contained in this Presentation, such results or developments may not be indicative of results or developments in future periods. The Company expressly disclaims any obligation or commitment to disclose updates or revisions to any forward-looking statement contained herein to reflect any change in the Company's expectations in relation thereto or any change in events, conditions, or circumstances on which such statement is based. By receiving this Presentation, the user acknowledges and agrees to be bound by the above terms, conditions, limitations, and restrictions.

In case of any discrepancies or differences in interpretation between the Italian and English versions of the presentation, the Italian version shall prevail and be considered the most reliable.

PREDICT

Bari

Viale Adriatico, 4 c/o Fiera del Levante - Pad. 105 | +39 080 893 3754

Milano

Piazza Gae Aulenti 1, Torre B | +39 02 9713 0325

predictcare.it

INVESTOR RELATIONS MANAGER

Angelo Ceci, CFO & IRM - Predict

E-mail: investor.relator@predictcare.it

Tel. +39 080 893 3754

INVESTOR RELATIONS ADVISOR

Chiara Cardelli, Senior Associate - KT&Partners

E-mail: ccardelli@ktepartners.com

Tel. +39 3387129015